PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers

Several clinical trials are investigating the use of immune-targeted therapy with Programmed death ligand-1 (PD-L1) inhibitors for colorectal cancer (CRC), with promising results for patients with mismatch repair (MMR) deficiency or metastatic CRC. However, the prognostic significance of PD-L1 expre...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Pers Med
Egile Nagusiak: Siraj, Abdul K., Parvathareddy, Sandeep Kumar, Annaiyappanaidu, Padmanaban, Haqawi, Wael, Al-Rasheed, Maha, AlManea, Hadeel M., AlHussaini, Hussah F., Al-Dayel, Fouad, Al-Kuraya, Khawla S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7911042/
https://ncbi.nlm.nih.gov/pubmed/33530623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11020073
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak